UFH stands for unfractionated heparin, a blood-thinning medication used in hospitals to treat and prevent blood clots. It is the most widely used intravenous anticoagulant in clinical medicine, prescribed for conditions ranging from deep vein thrombosis to heart attacks to strokes. Unlike newer blood thinners that come in pill form, UFH is given by injection or continuous IV drip, which allows doctors to adjust its effects quickly and precisely.
Where UFH Comes From
Heparin is not a synthetic drug. It’s a naturally occurring substance found in animal tissue, most commonly purified from pig intestines. Chemically, it belongs to a family of molecules called glycosaminoglycans, which are long chains of sugar units. UFH is called “unfractionated” because the full range of molecule sizes is preserved during manufacturing, resulting in a mix of chains with molecular weights ranging from 5,000 to 40,000 daltons. This stands in contrast to low-molecular-weight heparins (LMWHs), which are processed further to isolate only the smaller chains.
How UFH Prevents Blood Clots
UFH doesn’t thin the blood directly. Instead, it supercharges a natural protein in your bloodstream called antithrombin. Antithrombin’s job is to shut down clotting enzymes, but on its own, it works slowly. When UFH binds to antithrombin, it triggers a shape change in the protein that increases its clot-blocking ability by up to 1,000 times. This turbocharged antithrombin then latches onto key clotting enzymes, particularly thrombin and factor Xa, and neutralizes them. The result is a powerful, rapid suppression of clot formation that kicks in within minutes of administration.
When UFH Is Used
UFH has a broad range of uses, nearly all of them in hospital settings. The most common include:
- Venous thromboembolism: treating blood clots in the legs (deep vein thrombosis) or lungs (pulmonary embolism)
- Acute coronary syndrome: preventing new clots during a heart attack or unstable angina
- Acute ischemic stroke: limiting clot-related damage in the brain
- Heart surgery: preventing clotting when blood circulates through a heart-lung bypass machine
- Irregular heart rhythms: reducing stroke risk in certain arrhythmias
One reason UFH remains a go-to choice despite newer alternatives is its short duration of action. If bleeding occurs or surgery is needed, the drug wears off quickly, and it can also be reversed with a specific antidote called protamine sulfate (1 mg of protamine neutralizes roughly 100 units of heparin). This level of control is critical in emergency and surgical settings.
How UFH Is Given and Monitored
For most conditions, UFH is delivered as a continuous intravenous drip, starting with an initial loading dose followed by a steady infusion. Doses are calculated by body weight. A typical regimen for treating blood clots uses a loading dose of 80 units per kilogram, then a maintenance infusion of 18 units per kilogram per hour. For a person weighing about 70 kg (154 lbs), that translates to roughly 5,600 units upfront and 1,260 units per hour. Subcutaneous injection is an alternative when IV access isn’t practical.
Because UFH’s effect on clotting varies from person to person, it requires frequent blood testing. The standard test is called the activated partial thromboplastin time, or aPTT. Doctors aim for a result that is 1.5 to 2.5 times longer than the normal clotting time for that particular lab. In absolute numbers, that often works out to roughly 87 to 129 seconds, though the target varies by institution. During open-heart surgery, where much higher doses are needed, a different bedside test called the activated clotting time (ACT) is used instead, with a target above 450 seconds.
UFH vs. Low-Molecular-Weight Heparins
LMWHs like enoxaparin have largely replaced UFH for routine outpatient use. They’re easier to manage because they have a more predictable effect in the body, don’t require constant blood monitoring, and can be self-injected at home. Their half-life is longer and more stable, typically 3 to 5 hours, making once or twice-daily dosing feasible.
UFH still holds key advantages in specific situations. Its short, controllable duration makes it safer for patients who might need emergency surgery or who are at high bleeding risk. It’s also preferred for patients with severe kidney problems, since LMWHs are cleared through the kidneys and can accumulate to dangerous levels when kidney function is impaired. And in pregnancy, UFH is considered safe for the fetus because its large, variable-sized molecules do not cross the placenta. Studies in animal models have confirmed that therapeutic levels of heparin in the mother produce no detectable anticoagulant effect in the fetus.
The Main Risk: Heparin-Induced Thrombocytopenia
The most serious complication unique to heparin therapy is a condition called heparin-induced thrombocytopenia, or HIT. Paradoxically, this blood thinner can trigger the immune system to form antibodies that actually activate platelets and cause dangerous clotting. Up to 8% of patients receiving heparin develop these antibodies, but only 1 to 5% go on to develop the full syndrome with a significant drop in platelet count. Of those, roughly one-third will develop a serious blood clot.
HIT typically shows up 5 to 10 days after starting heparin, though it can appear sooner in people who have received heparin within the past 100 days. The hallmark sign is a platelet count that drops by more than 50% from baseline. Doctors use a scoring system called the “4 T’s” to assess the likelihood: the degree of platelet drop (Thrombocytopenia), Timing of onset, presence of Thrombosis, and whether oTher causes of low platelets have been ruled out. If HIT is suspected, all heparin products are stopped immediately and an alternative blood thinner is used.
The risk of HIT is higher with UFH than with LMWHs. In surgical patients receiving preventive doses, the incidence runs about 5% with UFH compared to 0.5% with LMWH. Surgical patients, especially those undergoing heart or orthopedic procedures, face a higher risk than medical patients, where the incidence is closer to 0.8%.
UFH in Surgery
Cardiopulmonary bypass surgery, where a machine temporarily takes over the work of the heart and lungs, requires high doses of UFH to prevent massive clotting on the machine’s artificial surfaces. A typical loading dose is 300 units per kilogram, substantially more than what’s used for treating blood clots. The activated clotting time is checked before the heparin dose, again 15 to 30 minutes after, and then every 30 minutes throughout the procedure. Once surgery is complete, protamine is given to reverse the heparin’s effect, and the clotting time is rechecked to confirm it has returned to normal.